
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
AB Science
Amyotrophic Lateral Sclerosis
The objective is to compare the efficacy and safety of masitinib in combination with
riluzole versus matched placebo in combination with riluzole for the treatment of
Amyotrophic Lateral Sclerosis (ALS). expand
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS). Type: Interventional Start Date: Feb 2021 |
|
Exercise and Emotional Learning in Posttraumatic Stress Disorder
Christal L Badour
PTSD
The goal of this clinical trial is to test how exercise affects learning and memory
processes relevant to the treatment of PTSD. Participants will complete a baseline intake
followed by two experimental sessions. During the first experimental session,
participants will undergo an MRI session of ima1 expand
The goal of this clinical trial is to test how exercise affects learning and memory processes relevant to the treatment of PTSD. Participants will complete a baseline intake followed by two experimental sessions. During the first experimental session, participants will undergo an MRI session of imaginal exposure to traumatic memory cues followed by 30-minutes of moderate intensity exercise or low intensity exercise. Participants will complete a second session of imaginal exposure with MRI 24 hours later. Type: Interventional Start Date: May 2024 |
|
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple1
Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an
allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell
maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the
effectiveness of CB-011 in treating multiple myelom1 expand
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory). Type: Interventional Start Date: Feb 2023 |
|
Imatinib TDM in GIST
Reema A. Patel
Gastrointestinal Stromal Tumors
Imatinib can lead to long recurrence free survival in patients diagnosed with
gastrointestinal stromal tumors (GIST); however side effects can significantly hinder
quality of life for our patients. This study will use therapeutic drug monitoring to
improve quality of life and symptoms and assess ho1 expand
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored. Type: Interventional Start Date: Mar 2024 |
|
A University-Community Partnership to Reduce Exposure to Disinfection Byproducts In Appalachia
Anna Hoover
Disinfection By-products
Appalachian Kentuckians in Martin and Letcher Counties are grappling with a
health-threatening drinking water crisis arising from exposures to disinfection
by-products (DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs),
chlorate, and other compounds that have been associated with1 expand
Appalachian Kentuckians in Martin and Letcher Counties are grappling with a health-threatening drinking water crisis arising from exposures to disinfection by-products (DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs), chlorate, and other compounds that have been associated with a variety of adverse health effects, including increased risk of bladder cancer and cardiovascular birth defects. This study implements a multi-stakeholder, multi-method approach to improve understanding of, characterize spatial and temporal variations in, and reduce exposure to DBPs in these Appalachian Kentucky counties. Type: Interventional Start Date: Feb 2022 |
|
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
Timothy Mullett
Cancer
Health Care Utilization
The C4 program aims to provide a multi-level intervention program (Patient Level,
Healthcare Team and Healthcare System Level) that improves the coordination of care with
supportive/ancillary care providers and community services through the use of patient
navigation and a digital needs assessment1 expand
The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services. Type: Interventional Start Date: Feb 2024 |
|
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Dennis M. McNamara, MD, MS
Peripartum Cardiomyopathy, Postpartum
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5
months postpartum in a randomized placebo controlled trial of bromocriptine therapy to
evaluate its impact on myocardial recovery and clinical outcomes. Given that
bromocriptine prevents breastfeeding, an additi1 expand
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort. Type: Interventional Start Date: Jul 2022 |
|
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutan1
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for1 expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |